Tran Capital Management L.P. Has $11.01 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Tran Capital Management L.P. lowered its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 50.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,436 shares of the medical research company's stock after selling 62,677 shares during the quarter. IQVIA makes up approximately 1.5% of Tran Capital Management L.P.'s holdings, making the stock its 25th biggest position. Tran Capital Management L.P.'s holdings in IQVIA were worth $11,007,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. American National Bank & Trust purchased a new position in IQVIA in the first quarter valued at about $26,000. ST Germain D J Co. Inc. lifted its position in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA in the fourth quarter worth about $39,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the fourth quarter worth about $44,000. Finally, Zions Bancorporation N.A. lifted its position in shares of IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. HSBC cut IQVIA from a "buy" rating to a "hold" rating and reduced their price target for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. UBS Group cut their price objective on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Barclays cut their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. Finally, Citigroup reissued a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Price Performance

IQV stock traded up $0.05 during midday trading on Thursday, reaching $158.88. 1,584,470 shares of the company's stock traded hands, compared to its average volume of 1,613,803. The company has a 50-day simple moving average of $147.21 and a two-hundred day simple moving average of $178.30. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The company has a market cap of $27.49 billion, a price-to-earnings ratio of 21.18, a PEG ratio of 1.99 and a beta of 1.28. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the company earned $2.54 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.